A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53–HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By...

Full description

Bibliographic Details

Published in:	eLife
Main Authors:	Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Thérèse Valat, Masato Murakami, Stephan Ruetz, Daniel A Guthy, Caroline Rynn, Michael R Jensen, Marion Wiesmann, Joerg Kallen, Pascal Furet, François Gessier, Philipp Holzer, Keiichi Masuya, Jens Würthner, Ensar Halilovic, Francesco Hofmann, William R Sellers, Diana Graus Porta
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2015-05-01
Subjects:	translational oncology predictive signature p53 HDM2
Online Access:	https://elifesciences.org/articles/06498